1. Home
  2. SCLX vs DOMH Comparison

SCLX vs DOMH Comparison

Compare SCLX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.82

Market Cap

52.9M

Sector

Health Care

ML Signal

HOLD

Logo Dominari Holdings Inc.

DOMH

Dominari Holdings Inc.

HOLD

Current Price

$2.93

Market Cap

47.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
DOMH
Founded
2011
1967
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.9M
47.2M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
SCLX
DOMH
Price
$6.82
$2.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.1K
109.9K
Earning Date
04-10-2026
05-12-2026
Dividend Yield
N/A
22.56%
EPS Growth
N/A
34.03
EPS
N/A
N/A
Revenue
N/A
$123,104,000.00
Revenue This Year
$122.52
N/A
Revenue Next Year
$186.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
578.41
52 Week Low
$3.95
$2.69
52 Week High
$34.27
$8.40

Technical Indicators

Market Signals
Indicator
SCLX
DOMH
Relative Strength Index (RSI) 45.53 46.98
Support Level $6.20 $2.77
Resistance Level $7.77 $3.52
Average True Range (ATR) 0.72 0.18
MACD 0.10 0.01
Stochastic Oscillator 71.43 34.00

Price Performance

Historical Comparison
SCLX
DOMH

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.

Share on Social Networks: